The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility.
Name:
Menhofer et al_final.pdf
Size:
1.673Mb
Format:
PDF
Description:
Open Access publication
Name:
journal.pone.0112542.s001.tif
Size:
1.991Mb
Format:
TIFF image
Description:
supporting figure S1
Name:
journal.pone.0112542.s002.tif
Size:
6.208Mb
Format:
TIFF image
Description:
supporting figure S2
Name:
journal.pone.0112542.s003.tif
Size:
1.225Mb
Format:
TIFF image
Description:
supporting figure S3
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Menhofer, Magdalena HKubisch, Rebekka
Schreiner, Laura
Zorn, Matthias
Foerster, Florian
Mueller, Rolf
Raedler, Joachim O
Wagner, Ernst
Vollmar, Angelika M
Zahler, Stefan
Issue Date
2014
Metadata
Show full item recordAbstract
A major player in the process of metastasis is the actin cytoskeleton as it forms key structures in both invasion mechanisms, mesenchymal and amoeboid migration. We tested the actin binding compound Chondramide as potential anti-metastatic agent.Citation
The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. 2014, 9 (11):e112542 PLoS ONEAffiliation
Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbru ¨ cken, Germany.Journal
PloS onePubMed ID
25391145Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0112542
Scopus Count
The following license files are associated with this item:
Related articles
- In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
- Authors: Menhofer MH, Bartel D, Liebl J, Kubisch R, Busse J, Wagner E, Müller R, Vollmar AM, Zahler S
- Issue date: 2014 Nov 1
- The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.
- Authors: Citterio C, Menacho-Márquez M, García-Escudero R, Larive RM, Barreiro O, Sánchez-Madrid F, Paramio JM, Bustelo XR
- Issue date: 2012 Oct 2
- Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.
- Authors: Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH
- Issue date: 2013
- Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.
- Authors: Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, Schmoeckel E, Mayr D, Schmitt S, Huettel S, Zischka H, Mueller R, Vollmar AM
- Issue date: 2014 Aug 28
- Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway.
- Authors: Lang JY, Chen H, Zhou J, Zhang YX, Zhang XW, Li MH, Lin LP, Zhang JS, Waalkes MP, Ding J
- Issue date: 2005 May 1